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Summary 
The ubiquitous cellular distribution of certain cytokine 
receptors has hampered attempts to define the physio- 
logically important cell-specific functions of cytokines 
in vivo. Herein, we report the generation of transgenic 
mice that express a dominant-negative IFNy receptor 
a chain mutant under the control of either the human 
lysoxyme promoter or the murlne Ick proximal pro- 
moter, which display tissue-specific unresponsive- 
ness in the macrophage or T cell compartments, re- 
spectively, to the pleiotropic cytokine, IFNT. We utilize 
these mice to identify previously undefined cellular 
targets of IFNy action in the development of a murine 
antimicrobial response and the mixed lymphocyte re- 
action. Moreover, we identify the macrophage as a crit- 
ical responsive cell in manifesting the eff ects of IFNy in 
regulating CD4+ T helper subset development. These 
studies thus represent a novel approach to studying 
the cell-specific actions of an endogenously produced 
pleiotropic cytokine in vivo. 
Introduction 
The definition of the biologic roles of interferon y (IFNy) has 
been facilitated by the availability of purified recombinant 
IFNy and neutralizing IFNy-specific monoclonal antibod- 
ies (MAbs) (Farrar and Schreiber, 1993). Recently, the 
generation of mice lacking either the IFNy or IFNy receptor 
genes has allowed for a broader appreciation of the in vivo 
functions of IFNy (Dalton et al., 1993; Huang et al., 1993). 
However, since IFNy receptors are expressed on nearly 
all cells, the current technologies have been unable to 
define the cell-specific functions of this cytokine in vivo. 
We have used dominant-negative mutant forms of the 
IFNy receptor a chain to elucidate the cell-specific actions 
of IFNy (Dighe et al., 1993, 1994). Overexpression of a 
cytoplasmically truncated form of the IFNr receptor a 
chain in homologous cells eliminated cellular responses 
to IFNr in vitro (Dighe et al., 1993). When this technique 
was used with cultured murine fibroblasts, the resulting 
cells became IFNy unresponsive and failed to induce a 
variety of IFNy-dependent cellular responses in vitro. 
These included induction of IRF-1 gene transcription, ex- 
pression of inducible nitric oxide (NO) synthase, up-regu- 
lation of major histocompatibility complex (MHC) class I 
protein expression, and induction of an antiviral response. 
More recently, we expressed dominant-negative IFNy re- 
ceptors in a transplantable murine fibrosarcoma and used 
these cells to elucidate a novel role for IFNy in the develop 
ment of anti-tumor responses in mice (Dighe et al., 1994). 
Using Meth A tumor cells that overexpressed a cytoplasmi- 
tally truncated IFNy receptor a chain, we showed that 
IFNy-insensitive Meth A cells displayed enhanced tumori- 
genicity compared with control Meth A cells and resisted 
rejection in endotoxin-treated and immune mice. In addi- 
tion, IFNy-insensitive tumor cells were poorly immuno- 
genic. These results demonstrated that IFNy has direct 
effects on tumor cell immunogenicity and thus plays an 
important role in promoting tumor cell recognition and 
elimination. 
Although the two previous studies validated the use of 
dominant-negative IFNy receptors as a means of selec- 
tively eliminating the response of specific cell populations 
to IFNr, they required the use of transfected cultured cells. 
To explore whether tissue-specific IFNy unresponsive- 
ness could be induced in intact animals, we generated 
transgenic mice in which adominant-negative IFNy recep- 
tor mutant was targeted to specific cell types using tissue- 
specific promoters. Herein, we document the generation 
and characterization of transgenic mice with targeted IFNy 
unresponsiveness in either the macrophage or Tcell com- 
partment. Moreover, we demonstrate the functional con- 
sequences of cell-specific IFNy insensitivity and define 
the primary cellular targets of the actions of IFNr in the 
development of antimicrobial and allogeneic responses 
and identify one of the cell-specific actions of IFNy in facili- 
tating development of CD4+ T helper (Th) cell subsets. 
Results 
Generation of Transgenic Mice Expressing a 
Dominant-Negative Form of the IFNy Receptor 
a chain in Macrophages 
Based on the well-established role of IFNy in affecting 
macrophage function in vitro, we chose initially to target 
IFNy unresponsiveness to the macrophage compartment. 
We used a cDNA encoding a previously characterized cy- 
toplasmically truncated dominant-negative form of the 
IFNy receptor a chain (Dighe et al., 1993). To enhance 
transgene detection, the cDNA was modified at its 5’ end 
to encode the myc protc-oncogene epitope recognized by 
the MAb 9ElO. This cDNA was placed under the control 
of the human lysozyme promoter for selective expression 
in macrophages. FACS analysis of resident peritoneal 
macrophages derived from transgenic mice showed that 
the transgene was expressed at high levels on F4/80- 
positive cells (Figure 1). No significant 9ElO staining was 
seen on the F4/80-negative population, demonstrating se- 
lective expression in the resident macrophage lineage. 
Thioglycollate-elicited peritoneal exudate cells (PECs) did 
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Figure 1. Expression of Epitope-Tagged Truncated Murine IFNy Re- 
ceptor a Chain in rPECs of Macrophage-Targeted Transgenic Mice 
rPECs were obtained from transgene-positive hLP-myc-mgRAIC 
mice and littermate controls. Expression of the epitope-tagged 
transgene was determined by two-color flow cytometry using biotinyl- 
ated myc-tag-specific 9E10 MAb and streptavidin-PE (SAPE) and 
FITC-conjugated anti-F4/60. Flow cytometry was conducted as de- 
scribed in Experimental Procedures. 
not show 9ElO staining, suggesting that transgene ex- 
pression was limited to mature resident macrophages. 
Flow cytometric analysis of peripheral blood revealed low 
level 9ElO staining in a subset of the Mac-l+ cells (3%- 
6% of total) but not on T cells (CD3+), B cells (62207, 
neutrophils (Gr-1’) or natural killer (NK) cells (5E6’) (data 
not shown). In whole splenocyte populations, the epitope- 
tagged receptor was detectable only on Mac-l+ cells, but 
at low levels. Identical patterns of expression were ob- 
served in three lines of mice derived from distinct founders. 
Normal numbers of CD3+, B220+, and NK cells were pres- 
ent in blood, thymus, and spleen in comparison to non- 
transgenic controls, demonstrating that no significant al- 
teration of hematopoetic cell development had occurred 
secondary to transgene expression. Thus, the human lyso- 
zyme promoter-driven construct used in this study directed 
expression of the epitope-tagged truncated murine IFNr 
receptor a chain specifically to a subset of cells of the 
macrophage lineage. 
Expression of Truncated IFNy Receptors in Resident 
Peritoneal Macrophages Results in Functional 
Nonresponsiveness to IFNy 
We next examined the in vitro responses of resident perito- 
neal exudate cells (rPECs) to IFNy. Culture of rPECs de- 
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Figure 2. Functional Characterization of Mice with Targeted Expres- 
sion of a Dominant-Negative IFNy Receptor in Macrophages 
(A) IFNy unresponsiveness of rPECs in macrophage-targeted trans- 
genie mice. PECs (10s) from hLP-myc-mgRAIC transgene-positive 
mice or littermate controls were seeded in a 96well tissue culture 
plate and allowed to adhere for 2 hr. Adherent PECs were then washed 
and stimulated with either LPS (10 @ml), rMulFNr (1000 IRU/ml), 
or rHulFNar.o (1009 IRUlml), or various combinations of the above 
reagentsat thesameconcentration. After46 hrofstimulation,superna- 
tants were harvested and the level of nitrite determined by the Greiss 
reaction (Green et al., 1962). 
(9) Increased susceptibility of macrophage-targeted transgenic mice 
to Listeria monocytogenes infection. Transgene-positive hLP-myc- 
mgRAIC mice or littermate controls were infected with 5 x lo5 cfu of 
Listeria monocytogenes intraperitoneally. On day 5, bacteria in the 
spleens and livers of infected mice were quantitated by colony counts 
of homogenates plated on BHI agar. At this time, 33% of the transgene- 
positive mice had died (3 of 9) whereas none of the transgene-negative 
group had died (0 of 10). In mice treated with the anti-IFNr MAb H22, 
44% (4 of 9) of the transgene-positive mice and 40% (4 of 10) of 
transgene-negative mice died by day 5. 
rived from nontransgenic littermate control mice with 
the combination of IFNy and lipopolysaccharide (LPS)- 
induced expression of NO synthase (INOS), leading to the 
production of 5.4 nmol nitrite/105cells (Figure 2A). In con- 
trast, rPECs from the macrophage-targeted transgenic 
mice (hLP-myc-mgRAIC) cultured with the combination 
of IFNy and LPS produced only 0.3 nmol nitrite/lo5 cells, 
an amount that was comparable to the level of nitrite pro- 
duced with LPS alone (0.2 nmol/105 cells). The lack of 
iNOS induction in rPECs from transgenic mice wasspecifi- 
tally due to IFNy unresponsiveness, since the cells re- 
sponded to the combination of IFNa plus LPS in a manner 
that was comparable to rPECs isolated from littermate 
controls (4.1 and 5.4 nmolllo5 cells, respectively). Thiogly- 
collate-elicited PECs from transgene-positive and litter- 
mate control mice responded to IFNy as monitored by 
induction of MHC class II proteins, a finding that was pre- 
dicted by transgene expression data. IFNy respon- 
siveness was not altered in T or B cells from macrophage- 
targeted transgenic mice, as evidenced by monitoring 
IFNy-dependent MHC class I protein enhancement (data 
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not shown). Thus, expression of adominant-negative IFNy 
receptor a chain under control of the human lysozyme 
promoter produced a state of functional unresponsiveness 
to IFNy, which was localized to resident macrophages. 
Increased Susceptibility to Listeria monocytogenes 
in Mice Expressing Truncated IFNy Receptors 
in Macrophages 
To assess the in vivo consequences of functional IFNy 
unresponsiveness of resident macrophages, we exam- 
ined responses of transgene-positive and control mice to 
infection with Listeria monocytogenes. IFNy is required 
for the initiation of antimicrobial responses and its site of 
action is presumed to be the macrophage (Buchmeier and 
Schreiber, 1985; Bancroftet al., 1991). To test this hypoth- 
esis formally, we infected transgene-positive or littermate 
control mice with 5 x lo5 colony-forming units (cfu) of 
Listeria. This dose of Listeria was sublethal for control 
mice(Oof lOdead byday5). Incontrast, 33%oftransgene- 
positive animals (3 of 9) died by day 5. Bacterial titers 
in the spleen and liver of transgene-positive mice were 
approximately lOO-fold greater than observed in control 
animals (Figure 28). As expected, pretreatment of control 
mice with a neutralizing antibody to IFNy increased their 
susceptibility to Listeria (4 of 10 dead by day 5). Surviving 
antibody-treated control mice had Listeria titers lOO-fold 
higher than control mice. Anti-IFNy treatment of trans- 
gene-positive animals did not significantly alter lethality 
(4 of 9 dead)or bacterial titers. Thus, whole animal neutral- 
ization of IFNy produced similar effects to those seen by 
selectively inducing a state of IFNy unresponsiveness in 
the resident macrophage. These results suggest that the 
resident macrophage is the principal cell required to initi- 
ate an IFNy-dependent anti-Listeria response. 
Generation of Transgenic Mice Expressing a 
Dominant-Negative Form of the IFNy 
Receptor Selectively in T Cells 
Resolution of Listeria infection requires induction of cell- 
mediated immunity that is dependent on the induction of 
the CD4+ Thl subset. IFNy has been suggested to regulate 
Th phenotype development at the level of the T cell (Gajew- 
ski and Fitch, 1988; Seder et al., 1993; Schmitt et al., 
1994). To examine this issue in more detail, we generated 
transgenic mice with selective IFNy unresponsiveness in 
T cells by driving the expression of the epitope-tagged 
dominant-negative IFNy receptor a chain with the Ickprox- 
imal promoter. Expression of the epitope-tagged, trun- 
cated IFNy receptor in T cell-targeted transgenic mice 
(Ick-myc-mgRAIC) was restricted to the T cell lineage. 
Several lines of transgenic mice demonstrated expression 
of the epitope-tagged transgene in peripheral T cells. The 
Ick proximal promoter has been previously demonstrated 
to direct the expression of heterologous cDNAs to the thy- 
mocyte compartment. The expression of the truncated 
IFNy receptor in the peripheral T cells in several lines of 
Ick-myc-mgRAIC mice was likely due to the prolonged 
half-life of the mutant IFNy receptor protein, which lacks 
those portions of the receptor required for efficient inter- 
nalization and degradation. Peripheral blood CD3+ cells 
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Figure 3. Expression of Epitope-Tagged Truncated Murine IFNy Re- 
ceptor a Chain in the Peripheral Blood of T Cell-Targeted Transgenic 
Mice 
Peripheral blood was obtained from transgene-positive Ick-myc- 
mgRAIC mice and littermate controls. Expression of the epitope- 
tagged transgene was determined by two-color flow cytometry using 
biotinylated myc-tag-specific 9ElO MAb and SAPE and FITC- 
conjugated anti-CDb. Flow cytometry was conducted as described 
in Experimental Procedures. 
from these lines expressed high levels of the epitope- 
tagged receptor (9ElO staining), as measured by flow cy- 
tometry (Figure 3). The epitope-tagged receptor was also 
expressed at high levels in the spleen and thymus on virtu- 
ally all CD3’ cells (data not shown). Normal distributions 
of CD3+, CD4+, CD8+, B220+, and NK cells were seen in 
thymus, spleen, and peripheral blood compared with non- 
transgenic controls. These results demonstrated that the 
epitope-tagged dominant-negative form of the IFNy recep- 
tor was selectively targeted to the T cell lineage and did not 
effect either general hematopoietic or specific lymphocyte 
lineage development. 
Expression of the Truncated IFNy Receptor in T Cells 
Produces a State of T Cell Functional 
Nonresponsiveness to IFNy 
Tcell responsiveness to IFNy in T cell-targeted transgenic 
mice was initially assessed by monitoring IFNy-dependent 
enhancement of MHC class I expression. Peripheral blood 
cells from nontransgenic littermates cultured in vitro in the 
presence of 1000 lRU/ml of murine IFNy showed in- 
creased MHC class I expression on both the CD3’ and 
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Figure 4. Specific Lack of IFNr-Induced Enhancement of MHC Class 
I on T Cells from T Cell-Targeted Transgenic Mice 
Peripheral blood of transgene-positive Ick-myc-mgRAIC and lit- 
termate control mice was cultured for 72 hr with 1000 IRUlml of either 
murine IFNy or human IFNu~x,. CDS+and B220+ cells were then exam- 
ined for MHC class I expression by flow cytometry using PE-conjugated 
anti-H-2Kd MAb as described in Experimental Procedures. Dotted lines 
represent the constitutive level of MHC class I expressed on cells 
incubated with medium alone. 
8220’ populations, as detected by flow cytometry (Figure 
4). In contrast, CD3+ ceils from T cell-targeted transgenic 
mice did not increase MHC class I expression in response 
to murine IFNy. This loss of IFNy responsiveness was spe- 
cific to the CD3+ population, since B220’ cells from Ick- 
myc-mgRAIC transgenic mice remained fully responsive 
to IFNy. The lack of IFNy responses in the transgenic T 
cells was not due to a generalized defect in the MHC class 
I synthesis pathway, since both CD3+ and B22O’cells from 
transgene-positive and control mice showed enhanced 
MHC class I expression in response to IFNa (data not 
shown). Like peripheral blood leukocytes, splenocytes 
from transgenic mice also showed specific IFNy unrespon- 
siveness that was restricted to the CD3+ population (data 
not shown). Peritoneal macrophages derived from the T 
cell-targeted transgenic mice showed normal induction 
of iN0.S in response to the combination of IFNr and LPS 
(data not shown). Thus, transgenic mice that express the 
dominant-negative form of the IFNy receptor under the 
control of the Ick proximal promoter show a selective state 
of functional unresponsiveness to IFNy, which localizes 
to the T cell compartment. 
To assess the functional consequences of eliminating 
IFNy responses in T cells, we examined allogeneic T cell 
proliferative responses in splenocytes derived from T cell- 
targeted transgenic and littermate control mice. Previous 
reports established that global elimination of cellular re- 
sponses to IFNy in vitro (either using neutralizing MAbs 
or by targeted disruption of the IFNr gene) augmented 
the proliferative responses of T cells to allogeneic stimuli 
(Bucy et al., 1988; Dalton et al., 1993). We therefore exam- 
ined responses of splenocytes from our H-2d haplotype 
transgenic mice or controls to irradiated H-2b haplotype 
allogeneic stimulator cells (Figure 5). Nontransgenic lit- 
termate control splenocytes proliferated when cultured 
with allogeneic stimulator cells. As expected, neutraliza- 
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Figure 5. Enhanced Proliferative Responses in MLR Cultures Estab- 
lished with Splenocytes from T Cell-Targeted Transgenic Mice 
MLRs were carried out by culturing 5 x lo5 responder H-2d spleno- 
cytes from transgene-positive Ick-myc-mgRAIC or littermate control 
mice with irradiated (2000 rads) C57BU6 (H-2b) splenocytes. Prolifera- 
tion was assessed by thymidine incorporation as described in Experi- 
mental Procedures. Neutralization of IFNy was carried out by the addi- 
tion of 100 uglml of the anti-IFNy MAb H22 at the initiation of the 
cultures. 
tion of IFNy with the anti-IFNy MAb H22 increased the 
proliferative response of responding cells by 3- to 4-fold. 
In contrast, Tcellsfrom H-2d Ick-myc-mgRAIC transgenic 
mice displayed an increased proliferative response, com- 
parable to that of the H2Btreated control cell cultures. No 
additional increase in proliferation of IFNy-unresponsive 
T cells occurred when IFNy was neutralized. This result 
thus demonstrates that the anti-proliferative action of IFNy 
in mixed lymphocyte reaction (MLR) cultures is the result 
of a direct effect of IFNy on T cells. 
To assess the in vivo consequences of T cell-specific 
IFNy unresponsiveness on the development of antimicro- 
bial responses, we infected T cell-targeted transgene- 
positive or littermate control mice with 5 x 1 O5 cfu of Liste- 
ria. None of the mice in either group died of the infection, 
indicating that both groups were capable of developing 
sterilizing anti-Listeria immunity (0 of 8 and 0 of 10 dead 
by day 5 for transgenic and control mice, respectively). 
Bacterial titers on day 5 in the spleen and liver of 
transgene-positive mice were similar to that of littermate 
control animals (data not shown). The ability of both groups 
of mice to produce sterilizing immunity to Listeria was 
demonstrated by the absence of Listeria cfu in the spleen 
and liver of the mice on day 10. As expected, pretreatment 
of transgene-positive or control mice with a neutralizing 
antibody to IFNr increased susceptibility to Listeria (4 of 
8 transgene-positive and 4 of 10 control mice dead by day 
5). Surviving H22-treated mice had Listeria titers lOO-fold 
higher than untreated transgene-positive or control mice 
(data not shown). Thus, in contrast with the results ob- 
tained using mice with targeted macrophage IFNy unre- 
sponsiveness, mice with targeted T cell IFNy unrespon- 
siveness had no defect in the ability to mount a full curative 
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anti-Listeria response. Since sterilizing immunity to Liste- 
ria is known to require development of a cell-mediated 
immune response, and since cell-mediated immunity is 
promoted by the Thl subset, our results suggest Thl sub- 
set induction occurs normally in transgenic mice with T 
cell-targeted IFNy responsiveness. 
Conditions during 
primary stimulation: 
None 
IL-4 
Control 
Ick-myc-mgRAIC 
Normal Th Phenotype Development of DO1 1 .lO TCR 
Transgenic T Cells Lacking IFNy Responsiveness 
A role for IFNy in Th phenotype development has been 
predicted from in vitro experiments that utilize T cells de- 
rived from TCR transgenic mice that express the DO1 1.10 
KJl-26+ TCR (Murphy et al., 1990). This system allows 
for experimental control over the antigen-presenting cell 
(APC), cytokine environment, and exposure to pathogens 
during primary T cell activation (Hsieh et al., 1992, 1993b). 
Using this system, IFNy has been found to be necessary 
but not sufficient for induction by heat-killed Listeria mono- 
cytogenes (HKLM) of a Thl phenotype (Hsieh et al., 1992, 
1993a, 1993b). Additionally, IFNy has been reported to 
exert a selective antiproliferative effect on Th2 and not 
Thl , thereby leading to the suggestion that IFNy may regu- 
late Th phenotype development by inhibiting Th2 forma- 
tion (Gajewski and Fitch, 1966). However, based on in 
vivo anti-Listeria responses manifest in mice with T cell- 
specific IFNy unresponsiveness, we questioned whether 
IFNy played a physiologically important role in Th pheno- 
type development. 
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Figure 6. Normal Th Cell Phenotype Development of T Cells Lacking 
IFNy Responsiveness 
Purified T cells (2.5 x 105/well) from DO1 1 .I0 Ick-myc-mgRAIC mice 
or DO1 1.10 control mice were stimulated with 0.3 pM OVA peptide 
presented by 6 x lb BALE/c splenocyles. Conditions added in the 
primary culture were media, IL-4 (20 U/ml), anti-IL-4 (IO &ml), IL-12 
(5 U/ml), HKLM (I x 107/ml). HKLM plus anti-IFNy (IO &ml), and 
HKLM plus anti-IL-12 (1:500 dilution polyclonal rabbit anti-IL-12). On 
day 7, the T cells were harvested, washed, counted, and restimulated 
at 2.5 x IO5 cells/well using 6 x lo8 SAL& splenocytes presenting 
0.3 uM OVA peptide in the absence of experimental conditions. Super- 
natants were collected at 46 hr and cytokine profiles assayed by 
ELISA. 
To explore this issue, we crossed the Ick-myc-mgRAIC 
transgenic mice to afi TCR transgenic mice expressing 
the DO1 1 .lO KJl-26’TCR. T cells derived from DO1 1 .lO 
up TCR transgenic mice are naive clonally restricted CD4+ 
T cells specific for a peptide of ovalbumin (323-339) (Mur- 
phy et al., 1990). The majority of the T cells derived from 
these doubly transgenic mice were CD4+, clonotype posi- 
tive, phenotypically naive (i.e., MEL-14+), and expressed 
high levels of the epitope-tagged dominant-negative IFNy 
receptor a chain. On the basis of IFNy-dependent MHC 
class I enhancement, these cells were IFNy unresponsive. 
Clonotype-positive CD4+ T cells from the doubly trans- 
genie mice were present in the periphery in amounts com- 
parable to mice transgenic only for the DO1 1 .lO TCR. 
ner that was indistinguishable from control TCR trans- 
genie T cells. Neutralization of either IFNy or IL-12 during 
primary stimulation prevented HKLM-induced Thl devel- 
opment, as observed previously (Hsieh et al., 1993a, 
1993b). Addition of IL-4 to primary cultures induced Th2 
development in both doubly transgenic T cells and control 
IFNy-responsive T cells. Neutralization of IL-4 during pri- 
mary activation produced a Thl phenotype in both doubly 
transgeneic and control T cells. Thus, regulation of Th 
phenotype development in IFNy-unresponsive T cells is 
unaltered in comparison to that of IFNy-responsive T cells. 
These results demonstrate that IFNy is not required by 
these T cells for IL-12-induced Thl development. 
IFNy Responsiveness by APCs Is Required for 
HKLM-Induced Thl Development 
We examined Th development in these cells using an The lack of role for T cell IFNy responsiveness suggested 
in vitro assay system. In this system, Thl and Th2 subsets that the APC may be the physiologic target of the actions 
are defined by the polarized production of IFNy but not of IFNy during Th phenotype development. Because of 
interleukin 4 (IL-4) and of IL-4 but not IFNy, respectively. limited expression of the dominant-negative transgene in 
Purified T cells from T cell-targeted IFNy-unresponsive splenic macrophages, we were unable to use APC derived 
doubly transgenic mice or control mice expressing only from the macrophage-targeted mice. To circumvent this 
the DO1 1 .lO transgenes were activated in vitro with OVA problem, we took advantage of the observation that 
peptide and irradiated BALBlc splenocytes and allowed DO1 1 .lO transgenic T cells respond to OVA peptide pre- 
todevelopfor 7 days. Following restimulation with antigen, sented either by H-2 or H-2b splenocytes. In initial control 
doubly transgenic T cells showed no substantial differ- experiments, we determined that under avariety of culture 
ences in IL-4 or IFNy production compared with control conditions there were no significant differences in prolifer- 
DO1 1 .lO transgenic T cells (Figure 6, top bars). IL-1 2 in- ation or cytokine production using either BALBlc (H-9 or 
duced Thl development of doubly transgenic T cells lack- 129 Sv (H-2q splenocytes as the APCs (data not shown). 
ing IFNy responsiveness in a manner similar to that ob- We then examined whether IFNy-unresponsive APC de- 
served with control TCR transgenic T cells. Furthermore, rived from spleens of 129s~ mice homozygous for the 
IFNy-unresponsive T cells expressed a Thl cytokine pro- targeted disruption of the IFNy receptor a chain (Huang et 
file when differentiated in the presence of HKLM in a man- al., 1993) could effect normal Th phenotype development. 
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Figure 7. Thl Phenotype Development in Response to Heat-Killed 
Listeria Requires IFNy Responsive APCs 
T cells (2 x 10S/well) were stimulated in the presence of added cyto- 
kines or anti-cytokine antibodies in 24-well plates with 0.3 uM OVA 
peptide presented by either 6 x 1 Oe 129 Sv splenocytes or splenocytes 
from mice lacking the IFNy receptor o chain. Cultures were maintained 
during the primary stimulation in the presence of the indicated condi- 
tions. On day 7, the T cells were harvested, washed, counted, and 
restimulated at 2.5 x lo5 cells/well using 6 x lo6 129 Sv splenocytes 
presenting 0.3 PM OVA peptide in the absence of experimental condi- 
tions. Supernatants were collected at 46 hr and cytokine profiles as- 
sayed by ELISA. 
DO1l.10 transgenic T cells were activated in vitro with 
OVA peptide and irradiated splenocytes derived from wild- 
type 129 Sv mice or 129 Sv mice lacking the IFNy receptor 
(TRKO). After incubation for 7 days, the Tcells were restim- 
ulated with OVA peptide and irradiated wild-type 129 Sv 
splenocytes. No substantial differences in IL-4 or IFNy 
production were observed between T cells primed using 
either control 129 Sv splenocytes or gRK0 splenocytes 
(Figure 7). Thus, the lack of APC IFNy responsiveness 
produced no significant differences in the default develop- 
ment of TCR transgenic T cells. 
In contrast, HKLM-induced Thl development required 
IFNy-responsive APCs. DO1 1 .lO transgenic T cells acti- 
vated with HKLM and control 129 Sv splenocytes devel- 
oped a strong Thl phenotype, as evidenced by the high 
levels of IFNy produced upon restimulation (Figure 7). In 
contrast, HKLM-induced Thl development was nearly ab- 
rogated when yRK0 splenocytes were used as APCs dur- 
ing the primary stimulation. Neutralization of IFNy or IL-12 
inhibited HKLM-induced Thl development as described 
(Hsieh et al., 1993a, 1993b). Furthermore, IL-4induced 
Th2 development and anti-IL-4-induced Thl development 
proceeded in a similar fashion regardless of whether the 
APCs were derived from 129 Sv control mice or IFNy re- 
ceptor-deficient mice. These results thus show that IFNy- 
responsive APCs are required for HKLM-induced Thl de- 
velopment. 
IFNy Increases IL-12 Production Induced by 
HKLM-Treated Macrophages 
The inability of IFNy-unresponsive APCs to support HKLM- 
induced Thl development suggested that IFNy may influ- 
ence IL-12 production. This question was examined by 
quantitating IL-12 production by HKLM-stimulated 129 Sv 
IFNy - + + 
HKLM - - + + 
Figure 8. IFNr Enhances Macrophage IL-12 Production Induced by 
Heat-Killed Listeria monocytogenes 
PECs (5 x 1oS) derived from 129 Sv IFNy receptor-deficient mice 
(rRK0). or hLP-myc-mgRAIC transgenic mice were stimulated with 
media or rMulFNv (1000 IRUlml) for 1 hr. PECs were then washed 
three times with media and HKLM (1 x 107/ml) was added. Superna- 
tants were harvested 48 hr following HKLM addition and IL-12 produc- 
tion quantitated by IL-12 p40 ELISA (Tripp et al., 1994). 
PECs that were cultured in the absence or presence of 
IFNy. HKLM induced production of 0.95 rig/ml of IL-12 p40 
in untreated 129 Sv PEC (Figure 8, top). In contrast, HKLM 
induced 13 times more IL-12 p40 in IFNy-treated PECs 
(12.3 nglml of IL-12 ~40). The enhancement of HKLM- 
induced IL-12 production specifically required the pres- 
ence of IFNy, since IFNa had no potentiating effects (data 
not shown). IFNy failed to enhance HKLM-induced IL-12 
production in PEC derived from mice lacking the IFNy 
receptor (yRK0, Figure 8, top). In addition, IFNy failed to 
enhance HKLM-induced IL-12 production in PEC derived 
from the hLP-myc-mgRAIC transgenic mice with macro- 
phage-specific IFNy unre.sponsiveness(Figure 8, bottom). 
Thus, we propose that IFNy acts to augment macrophage 
production of IL-12 and that this effect explains the ob- 
sewed requirement of IFNy forTh1 phenotype development. 
Discussion 
In this study, we demonstrate the generation of transgenic 
mice that express a dominant-negative IFNy receptor a 
chain mutant under the control of tissue-specific promot- 
ers and document that these mice exhibit tissue-specific 
unresponsiveness to IFNy. Using these mice, we identify 
the primary cellular targets of IFNy action in the well- 
defined models of murine Listeriosis and the MLR. More- 
over, we establish a role for IFNy in influencing CD4+ Th 
subset development. These studies thus represent a novel 
method to define the cell- or tissue-specific actions of an 
endogenously produced pleiotropic cytokine in vivo. 
Tissue-Specific IFNy Unresponsiveness 
663 
Many cytokines such as IFNy, IL-6, and tumor necrosis 
factor (TNF) induce their pleiotropic effects on a wide vari- 
ety of target cells due to the nearly ubiquitous expression 
of their respective cellular receptors. The widespread ex- 
pression of certain cytokine receptors in vivo is a major 
obstacle preventing the definition of the cell-specific physi- 
ologic roles of these cytokines. However, recent studies 
have begun to define the structure-function relationships 
of many cytokine receptors, including those for IFNy, IL-6, 
and TNF, and this information can be used to develop 
novel methodologies to study the functions of specific cy- 
tokines in vivo. In the case of the IFNy receptor, it is now 
known that at least two receptor subunits are required for 
IFNy signaling: the IFNy receptor a chain, which is re- 
quired for ligand binding, ligand trafficking, and signal 
transduction, and the IFNy receptor 6 chain, which is 
required primarily for signal transduction (Farrar and 
Schreiber, 1993). Moreover, the functionally important se- 
quences within the intracellulardomainsof the IFNy recep- 
tor a and 6 chains and the molecular interactions that 
effect initiation of the signal transduction cascade have 
been identified (Farraret al., 1991,1992; Cooket al., 1992; 
Greenlund et al., 1994, 1995). 
In the course of our structure-function studies of the 
IFNy receptor a chain, we observed that functionally inac- 
tive IFNy receptor a chain intracellular domain mutants, 
when overexpressed in homologous cells, functioned to 
inhibit cellular responses to ligand in a dominant-negative 
manner both in vitro (Dighe et al., 1993) and in vivo (Dighe 
et al., 1994). The observations suggested that it might 
be possible to target IFNy unresponsiveness to specific 
tissues by generating transgenic mice that utilize tissue- 
specific promoters to direct expression of the dominant- 
negative receptor. Forthis purpose, we used acytoplasmi- 
tally truncated mutant IFNy receptor a chain, since we 
had previously established that it was unable to traffic effi- 
ciently through the cell and accumulated at high levels on 
the plasma membrane (Dighe et al., 1993). To facilitate 
analysis of transgene expression, we used an epitope- 
tagged form of the mutant polypeptide. This epitope tag 
did not effect the ability of the mutant receptor to bind 
ligand or interact with the receptor 6 chain. 
The experiments presented herein demonstrate the va- 
lidity of this approach using two different cellular targets. 
The human lysozyme promoter was used to direct expres- 
sion of the dominant-negative IFNy receptor to the macro- 
phage compartment and the Ick proximal promoter was 
used for T cell-specific expression. This technique repre- 
sents a novel approach for disrupting cellular respon- 
siveness to a cytokine ligand in a tissue-specific manner. 
One advantage of this system is that it can accommodate 
promoters that drive transgene expression to a low degree 
in cell types other than those that have been targeted. 
Induction of unresponsiveness to ligand occurs only in 
cells expressing high levels of the dominant-negative re- 
ceptor mutant. In the case of the IFNy receptor a chain 
dominant-negative mutant, an approximately 1OO:l ratio 
of mutant to endogenous receptor is required for induction 
of IFNy unresponsiveness (Dighe et al., 1993). Therefore, 
low level expression of mutant receptors in nontargeted 
cell types will be functionally silent. This protocol may be 
generalizable to a variety of different receptor systems, 
especially systems in which functionally active receptors 
are composed of at least two subunits. 
The mice generated in our study have been useful in 
defining the physiologic cellular targets of the actions of 
IFNy in three different models. First, although macro- 
phages have been assumed to be a critical target of IFNy 
action in anti-Listeria responses, this concept has never 
been formally tested. The results reported here unequivo- 
cally demonstrate this concept in vivo. Moreover, owing 
to the specific targeting of IFNy unresponsiveness to resi- 
dent macrophages, thisstudy reveals the novel role played 
by these cells in initiating anti-Listeria responses. 
The pattern of expression observed in the human lyso- 
zyme promoter transgenics in this study differs in some 
respects from that observed in another study (S. C., 
D. Ft. G., L.-P. Chung and S. G., unpublished data), in 
which transgenic mice were generated using the human 
lysozyme promoter fragment placed upstream of a bac- 
terial chloramphenicol acetyltransferase (CAT) reporter 
gene. In these animals, CAT enzyme activity was detected 
in both thioglycollate-elicited macrophages and in cul- 
tured, but not freshly isolated, resident peritoneal macro- 
phages, resembling the expression pattern of the endoge- 
nous murine lysozyme gene (Keshav et al., 1991). The 
human lysozyme promoter also directed CAT expression 
in peritoneal thioglycollate-elicited PMN. In the transgenic 
mice analyzed in the current study, the human lysozyme 
promoter did not direct expression of the truncated IFNy 
receptor a chain to circulating PMN in normal uninfected 
mice. It is possible that the differences in expression pat- 
terns seen in these two studies reflect the different reporter 
genes and 3’ untranslated regions present in the two con- 
structs. 
Second, we have defined the role of IFNy in regulating 
the MLR. Previous studies showed that proliferation of T 
cells during a MLR was suppressed as a result of IFNy 
production in the culture (Bucy et al., 1966; Huang et al., 
1993; Dalton et al., 1993). However, since MLR cultures 
contain multiple functionally important cell types, these 
earlier studies did not identify the cellular target(s) of IFNy 
action. In the current report, we show that the effects of 
IFNy are directed at the T cell. These results suggest that 
IFNy may play an important regulatory role during CD6+ 
T cell generation. We speculate that this action of IFNy 
may serve to prevent CD6+ T cell responses from caus- 
ing immunopathologic reactions. Mice that specifically 
lack T cell IFNy responsiveness may be useful to examine 
the potential autoregulatory action of IFNy during CD8+- 
dependent antiviral or antitumor responses. 
Finally, the mice generated in the current study have 
been used to elucidate a role for IFNy in CD4’ Th cell 
phenotype development. IFNy is necessary for efficient 
Thl development (Hsieh et al., 1992, 1993a, 1993b), and 
was suggested to regulate the development of Th2 re- 
sponses by exerting an antiproliferative action specifically 
on Th2 cells (Gajewski and Fitch, 1988). This concept has 
been supported by studies of experimental murine Leish- 
maniasis. Neutralization of IFNy using either neutralizing 
anti-IFNy MAbs (Scott, 1991) or targeted disruption of the 
IFNy gene (Wang et al., 1994) leads to an exacerbating 
disease in normally resistant mice. In contrast, administra- 
tion of IFNy in vivo fails to cure susceptible BALBlc mice 
(Scott, 1991). Therefore, IFNy appears to be necessary 
but not sufficient for the development of Thl ceils both 
in vitro and in vivo. However, because of the ubiquitous 
cellular expression of IFNy receptors, these studies were 
unable todefine the cellularsiteof IFNy action under physi- 
ologic circumstances. 
In this report, we demonstrate that T cells made unre- 
sponsive to IFNy by the targeted specific in vivo expres- 
sion of dominant-negative IFNy receptors maintain the ca- 
pacity to differentiate towards both the Thl and Th2 
phenotypes. The in vitro development of Thl cells induced 
by IL-12 or HKLM remains intact regardless of whether 
these T cells can respond to IFNy. These results are sup- 
ported by the demonstration that mice with T cell-targeted 
IFNy unresponsiveness had no defect in their ability to 
develop sterilizing immunity to infection by Listeria mono- 
cytogenes, a process known to require intact Thl re- 
sponses. 
Previous work demonstrated that IFNy is necessary, but 
not sufficient, for HKLM-induced Thl development (Hsieh 
et al., 1993b). The actions of pathogens such as Listeria for 
promoting Thl development are macrophage dependent, 
and rely on the production of IL-12 (Hsieh et al., 1993a, 
1993b). Since we had demonstrated that T cell IFNy re- 
sponsiveness was not required for HKLM-induced Thl de- 
velopment, we asked whether IFNy acted on APCs to en- 
hance Thl development. Herein, we show that the APC 
responsiveness to IFNy is indeed required for HKLM- 
induced Thl development. Using splenocytes from mice 
homozygous for the targeted disruption of the IFNy recep- 
tor and control 129 Sv mice, we demonstrate that T cells 
activated in the presence of IFNy-unresponsive APCs fail 
to develop towards the Thl phenotype in response to 
HKLM. Further, we show that optimal IL-12 production 
by macrophages requires IFNy. Pretreatment of wild-type 
macrophages with IFNy before addition of HKLM strikingly 
enhanced IL-12 production. In contrast, IFNy-unrespon- 
sive macrophages failed to augment IL-12 production 
when exposed to IFNy plus HKLM. The IL-12 potentiating 
function of IFNy observed in this study is similar to that 
recently observed by Flesch et al. (1995) using IFNy recep- 
tor-deficient mice. 
In sum, our results identify the macrophage as a critical 
site of the action of IFNy in pathogen-induced Thl develop- 
ment. IFNy acts by enhancing the capacity of macro- 
phages to produce IL-1 2. We find no role for IFNy in these 
responses at the level of the T cell. Thus, we predict that 
an obligate role for IFNy in directing Thl phenotype would 
be observed only under conditions where IL-12 production 
is limiting. 
Experimental Procedures 
Reagents 
Recombinant murine IFNy was provided by Genentech. Incorporated 
(South San Francisco, California) and displayed a specific antiviral 
activity of 5.2 x lo8 IRlJlmg. Recombinant Human IFNar.o (specific 
activity 1.6 x 108 IUlmg), a nonspecies-specific form of human IFNa, 
was provided by Dr. G. Garotta of Hoffman-LaRoche AG (Basel, Swit- 
zerland). Hamster MAb specific for murine IFNy (H22) was produced 
and purified as described (Schreiber et al., 1985). The anti-myc 9ElO 
MAb (Eva” et al., 1985) was conjugated to biotin using the EN20 
biotinylating reagent (ENZO Biochemicals) as described (Sheehan et 
al., 1988). The IL4specific MAb 1 lBl1 (Ohara and Paul, 1985) has 
been previously described. Fluorescein isothiocyanate (FITC)- or phy 
coerythrin (PE)-conjugated anti-murine H-2Kd, anti-murine H-2Kb. anti- 
CD3, anti-CD4, anti-B220, anti-Gr-1, and anti-NK cell (derived from 
clone 5E6) were purchased from Pharmingen (San Diego, California). 
F4/80 is an antigen specifcfor cells of the macrophage lineage (Austyn 
and Gordon, 1981). FITC-conjugated anti-murine F4/80 MAb was pur- 
chased from Caltag. Hamster MAbs specific for ~35 (Red-T) and p40 
(TOSH) subunits of IL-12 were provided by Drs. E. Unanue and C. 
Tripp (St. Louis, Missouri) (Tripp et al., 1994). 
Mice 
Female BALB/c ByJ and C57BU6 mice 5-7 weeks of age were ob- 
tained from Jackson Labs (Bar Harbor, Maine). Female C3H/C57BU6 
Fl hybrid mice 3-4 weeks of age used in generation of transgenic 
mice were obtained from Harlan Sprague Dawley (Indianapolis. Indi- 
ana). 129Svand mice with a homozygousdeletionof the IFNy receptor 
gene(yRK0) (Huang et al., 1993) were provided by Dr. M. Aguet (Gen- 
entech, South San Francisco, California). Mice transgenic for the 
DO1 1 .I0 ap TCR (Murphy et al., 1990) were selected by staining pe- 
ripheral blood leukocytes with the anti-clonotype MAb KJ-126 (Marrack 
et al., 1983). 
Plasmid Construction 
Plasmids were constructed using standard procedures (Sambrook et 
al., 1989). We previously generated and characterized a cDNA encod- 
ing a cytoplasmically truncated form of the murine IFNy receptor a 
chain, which contains only three intracellular domain amino acids 
(Dighe et al., 1993). The truncated murine IFNy receptor mutant cDNA 
was subcloned into the pBSSKII(-) vector (Stratagene) and modified 
at its 5’ end by insertion of nucleotides that encode 13 residues of 
c-myc (SMEQKLISEEDLN), against which the QElO MAb is directed 
(Eva” et al., 1985). The myc sequences were inserted into the receptor 
such that they followed the signal sequence of the reeptor and first 
seven N-terminal amino acids to create a plasmid encoding the myc- 
tagged truncated murine IFNy receptor a chain (pBS.myc-mgRAIC). 
To ensure the myc tag did not interfere with the expression or the 
dominant-negative function of the truncated murine IFNy receptor, 
the myc-mgRAIC cDNA was subcloned into the pSFFV eukaryotic 
expression vector (Farrar et al., 1991) and stably transfected into mu- 
rine L929 fibroblast cells to create the L929.myc-mgRAIC cell line. 
This cell line expressed high levels of the myc-tagged truncated recep- 
tor as assessed by flow cytometry, using either the 9ElO MAb or the 
anti-murine IFNr receptor MAb GR-20. As expected, the transfected 
cells were completely unresponsive lo murine IFNy but maintained 
responsiveness to IFNa. 
The ~1017 vector used for transgenic expression in the T cell com- 
partment consists of the 3.2 kb Ick proximal promoter, which has been 
demonstrated to direct the expression of cDNAs to the thymocyte com- 
partment(Cooke etal., 1991). The transgenicconstruct wasgenerated 
by subcloning the myc-tagged truncated murine IFNy receptor cDNA 
into the BamHl site of the plU7vectortocreateplOl7,myc-mgRAIC. 
To generate the fragment used for microinjection, pl017,myc- 
mgRAIC was digested with Not1 and the 6.3 kb transgenic fragment 
isolated and purified by standard protocols (Cooke el al., 1991). 
The 3.5 kb human lysozyme promoter fragment has been demon- 
strated to direct expression of genes to the macrophage compartment 
(S. C., D. R. G., L.-P. Chung, and S. G., personal communication). The 
2.1 kb BamHI-Not1 fragment (containing the human growth hormone 
gene) of ~1017 (Cooke et al., 1991) was subcloned into the BamHl 
and Not1 sites of pBSSKII(-) to create pBS.hGH. The 3.5 kb Kpnl- 
Hincll human lysozyme promoter fragment from pUClS.hLP was then 
subcloned into the Kpnl and Hincll sites of pBS.hGH to create 
pBS.hLP-hGH. The myc-lagged truncated murine IFNy receptor 
cDNA was then subcloned into the BamHl site of this plasmid to create 
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pBS.hLP-myc-mgR-hGH. To generate the microinjected fragment, 
pBS.hLP-myc-mgRAIC-hGH was digested with Kpnl and Not I and 
the 6.6 kb transgenic fragment was isolated and purified. 
Generatlon of Transgenic Mice 
Transgenic mice were generated using standard techniques (Hogan 
et al., 1966) by microinjection of embyros derived from a BALBlc x 
C57BL/6/C3H Fl breeding. Transgene-positive animals were identi- 
fied by Southern blot analysis using a 0.6 kb Pstl-EcuRI fragment of 
the human growth hormone gene as a probe. Following the generation 
of founder animals, subsequent generations were maintained by 
breeding to BALB/c mice. Founder lines with the highest relative ex- 
pression of the myc-tagged truncated IFNy receptor transgene were 
used for the experiments presented here. Shown are representative 
data using the transgenic lines Ick-myc-mgRAlC-hGH-(1) and hLP- 
myc-mgRAlC-hGH-(9). 
Analysis of Transgene Expression by Flow Cytometry 
Two-color flow cytometry of peripheral blood, splenocytes, or PECs 
utilized biotinylated9ElOand FITC-conjugated CD3, CD4. CD6.8220, 
Gr-1 , 5E6, or F4/80-specific MAb. 
Analysis of Macrophage Responsiveness lo Murlne IFNT 
For analysis of NO production, 1 x lo5 PECs were seeded in a 96-well 
tissue culture plate (Costar, Cambridge, Massachusetts) and allowed 
to adhere for 2 hr. Adherent PECs were then washed three times with 
warmed media. PECs were stimulated with either LPS (10 pglml), 
rMulFNy(1000IRU/ml),orrHulFNa~~(1000IRU/ml),orvariouscombi- 
nations of the above reagents at the same concentration. After 48 hr 
of stimulation, supernatants were harvested and the level of nitrite 
determined by the Greiss reaction (Green et al., 1982). IL-12 produc- 
tion by PEC was performed essentially as previously described (Tripp 
et al., 1993). PEC (5 x 105) were seeded in a Costar 24-well tissue 
culture plate and allowed to adhere for 2 hr. Adherent PECs were 
washed three times with warmed media and were then stimulated with 
rMulFNy (1000 IRUlml) or rHulFNaA.o (1000 IRUlml) for 1 hr. PECs 
were then washed three times with warmed media and HKLM (1 x 10’1 
ml) was added. Supernatants were harvested 48 hr following HKLM 
addition and IL-1 2 production was quantitated using a SCID splenocyte 
bioassay (Ishida et al., 1992) and by capture ELISA for the IL-12 p40 
subunit (Tripp et al., 1994). 
Listeria 
Viable and heat-killed Listeria monocytogenes was provided by Dr. E. 
Unanue (St. Louis, Missouri). Listeria was diluted in saline and injected 
intraperitoneally at an infecting dose of 5 x lo5 cfu in 0.4 ml. Bacteria 
in the spleens and livers of infected mice were quantitated by colony 
counts of homogenates in PBS with 0.05% Triton X-l 00 plated on BHI 
agar. 
MLR 
MLR were carried out by culturing 5 x 1 O5 responder H-2d splenocytes 
with irradiated (2000 rads) C57BU6 (H-2b) splenocytes (stimulator 
cells) in a 96-well plate. Proliferation was assessed by thymidine incor- 
poration (Rogers et al., 1992). IFNy was neutralized by addition of 100 
pglml of anti-IFNy MAb H22 to the culture. 
Transgenic T Cell Purification 
CD4+ T cells were purified by FACS sorting with FITC-conjugated anti- 
CD4 and PEconjugated Mel-l 4 (Pharmingen) as previously described 
(Hsieh et al., 1995). Sorted T cells were routinely >98% CD4+/Mel-14+. 
T Cell Culture 
T cells were cultured in Iscove’s complete media as previously de- 
scribed (Hsieh et al., 1992). T cells (2.5 x 1OYwell) were stimulated in 
the presence of added cytokines or anti-cytokine antibodies in 24-well 
plates with 0.3 pM OVA peptide presented by 6 x 10 splenocyes 
derived from BALB/c, 129 Sv, or yRK0 mice (Dalton et al., 1993). 
Recombinant murine IL-4(Genzyme, Cambridge, Massachusetts) was 
used at 20 U/ml. IL-12 (Hoffman-LaRoche) was used at 5 U/ml. The 
anti-IL-4 MAb 11511 and anti-IFNy MAb H22 were used at 10 @ml. 
Rabbit anti-murine IL-12 polyclonal antisera (Hoffman-LaRoche) was 
used at a 1500 dilution. Heat-killed Listeria monocytogenes was used 
at 1 x 1 O’lml. On day 7. the T cells were harvested, washed, counted. 
and restimulated at 2.5 x lo5 cells/wefl by 6 x 1Q splenocytes pre- 
senting 0.3 PM OVA peptide in the absence of experimental conditions 
to determine the resulting Th cell phenotype. Supernatants were col- 
lected at 48 hr and cytokine profiles assayed by ELISA. 
Cytokine Assays 
Quantitation of IL-4 and IFNy were quantitated by ELISA as previously 
described (Hsieh et al., 1992). Standard curves were generated using 
recombinant cytokines from Genzyme. 
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